Thomas J. Walsh, MD, MBA, MS

Thomas J. Walsh, MD, MBA, MS

University of Washington Medical Center

Seattle, Washington

Dr. Thomas Walsh is a UW Professor and Vice Chair of Urology, Urology Section Head for UW Medical Center Northwest, and Director of the UW Men’s Health Center. His clinical interests include male reproductive and sexual medicine and surgery. He is the holder of the Endowed Professorship for Men’s Health, one of the only of its kind in the country.

Dr. Walsh completed his undergraduate training at the University of Oregon, where he graduated Phi Beta Kappa. He then received his medical degree from Northwestern University’s Feinberg School of Medicine, where he garnered the highest academic honors and was inducted into the Alpha Omega Alpha Honor Society. He completed his general and urologic surgical training at the University of Washington, during which time he served as a Ruth L. Kirschstein National Research Service Award Scholar and received a master’s degree in epidemiology at the UW School of Public Health. Dr. Walsh completed a fellowship in male infertility and erectile dysfunction at the University of California, San Francisco and directed the UCSF Center for Male Reproductive Health before returning to UW Medicine. During his time at UW, he founded the Men’s Health Center, has developed and maintained a robust and extramurally funded research program, and has trained several generations of residents and fellows.

Under Dr. Walsh’s leadership, the Men’s Health Center has become one of the busiest clinics of its kind in the country. He integrates the most advanced and minimally invasive diagnostic and treatment modalities into his practice. Dr. Walsh has been named as one of “Seattle’s Top Doctors” by both Seattle Magazine and Seattle Metropolitan Magazine, and is recognized as a leader among his peers.

Disclosures:

Talks by Thomas J. Walsh, MD, MBA, MS

Priapism: How Do We Manage and How Do We Learn How to Manage in 2024

Priapism: How Do We Manage and How Do We Learn How to Manage in 2024

Posted by | Oct 2024

Thomas J. Walsh, MD, MBA, MS, discusses practical strategies for evaluating, diagnosing, and managing ischemic priapism. He begins with an overview of the symptoms, diagnosis, associated risks, and standard treatment procedures for the management of ischemic priapism.

Dr. Walsh then turns to effective treatment options after intracavernosal phenylephrine and corporal aspiration fail. He outlines various types of distal shunting, corporal tunneling, penoscrotal decompression, and early prosthesis placement.

Dr. Walsh concludes by addressing the lack of standardized training for treating ischemic priapism. He outlines a simulation curriculum designed to quickly train and presents the results from the pilot study.

Read More
The Association Between Testosterone Treatment and Incident of Cardiovascular Events among Testosterone Deficient U.S. Veterans

The Association Between Testosterone Treatment and Incident of Cardiovascular Events among Testosterone Deficient U.S. Veterans

Posted by | Oct 2024

Thomas J. Walsh, MD, MBA, MS, provides a detailed examination of the relationship between testosterone treatment and the incidence of cardiovascular events among testosterone-deficient U.S. veterans.

In this 19-minute presentation, Dr. Walsh outlines the background of testosterone deficiency, noting ongoing concerns regarding its safety, particularly its potential to increase the risk of heart attacks, strokes, and other heart-related issues.

Drawing on data from a large cohort of U.S. veterans, Dr. Walsh discusses the incidence of cardiovascular events in patients undergoing testosterone therapy compared to those who do not receive such treatment. He discusses the methodology used in the study, including the selection of participants, the duration of follow-up, and the statistical analyses employed to control for confounding variables.

Read More
Priapism: How Do We Manage, and How Do We Learn How to Manage in 2024?

Priapism: How Do We Manage, and How Do We Learn How to Manage in 2024?

Posted by | Aug 2024

Thomas J. Walsh, MD, MBA, MS, discusses practical strategies for evaluating, diagnosing, and managing ischemic priapism. He begins with an overview of the symptoms, diagnosis, associated risks, and standard treatment procedures for the management of ischemic priapism.

Dr. Walsh then turns to effective treatment options after intracavernosal phenylephrine and corporal aspiration fail. He outlines various types of distal shunting, corporal tunneling, penoscrotal decompression, and early prosthesis placement.

Dr. Walsh concludes by addressing the lack of standardized training for treating ischemic priapism. He outlines a simulation curriculum designed to quickly train and presents the results from the pilot study.

Read More
Cannabis Use and Male Reproductive Health: Who Knew?

Cannabis Use and Male Reproductive Health: Who Knew?

Posted by | Aug 2024

Thomas J. Walsh, MD, MBA, MS, discusses the impact of habitual cannabis use on male fertility and reproductive health. He begins by establishing the current landscape and demographics of cannabis users globally, and the mechanisms behind its popularity as a recreational and medicinal substance.

Dr. Walsh then discusses emerging data on the impacts of cannabis on male fertility. He explores the deleterious influence of cannabis on Anandamide (nM) production and sperm morphology.

Dr. Walsh concludes with an examination of his own prospective analysis on the fertility of men presenting at his clinic for reproductive issues after current or past cannabis use. He underscores the importance of counseling patients using the available evidence, and strongly recommends against cannabinoid use while planning for a family.

Read More
Testosterone Treatment and Prostate Cancer Risk

Testosterone Treatment and Prostate Cancer Risk

Posted by | Jun 2024

Thomas J. Walsh, MD, MBA, MS, explores the relationship between testosterone treatment and risk for developing prostate cancer. Dr. Walsh begins by stating that he does not believe that testosterone treatment should be considered a risk factor for prostate cancer. He explains that according to the American Urological Association (AUA), testosterone therapy is appropriate treatment for patients with clinically significant testosterone deficiency after full discussion of potential adverse effects.

Dr. Walsh then outlines the positive and negative effects of testosterone therapy and shares data from a meta-analysis of the effect of testosterone replacement therapy on prostate cancer. He notes the issue of screening bias and compares the longitudinal comorbidities that showed virtually no difference in risk regardless of testosterone treatment.

Dr. Walsh concludes by sharing longitudinal data on cumulative testosterone treatment results that showed no increased risk of prostate cancer. Similarly, data did not show a statistical difference in prostate cancer risk according to the type of testosterone therapy a man received.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -